Press Releases
Novartis’ midostaurin achieves 60% response rate in advanced systemic mastocytosis
Novartis announced that The New England Journal of Medicine published data for PKC412 demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval , 49-70%; P<0.001) in patients with advanced systemic mastocytosis...
Press Releases
Merck, Premier Inc collaborate to improve care for osteoporosis patients
Merck and Premier Inc , a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis patients. ...
Press Releases
Pfizer says Two additional late stage studies of cholesterol drug met goals
Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR and SPIRE-FH , met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among...
Press Releases
EU approves Astrazeneca Plc’s New Antibiotic Zavicefta
AstraZeneca announced that the EC has granted marketing authorisation for Zavicefta , a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. The approval includes intravenous use of Zavicefta for...
Press Releases
FDA accepted Teva’s Fluticasone Propionate and Fluticasone Propionate RespiClick Inhalers
Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA has accepted for review the company’s new drug applications (NDAs) for two products for adolescent and adult patients with asthma. The first, fluticasone propionate/salmeterol, is a fixed-dose...
Press Releases
Novo Nordisk receives the EMA marketing approval of the mylife YpsoPump insulin pump
Novo Nordisk announces the EMA marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump cartridge NovoRapid®PumpCart®. The approval is a key milestone for the collaboration between Novo Nordisk and Ypsomed and their goal to deliver...
Press Releases
Teva and Antares Pharma Announce Launch of Generic Imitrex in the United States
Teva Pharmaceutical Industries Ltd. and Antares Pharma, Inc. announced the launch of the generic equivalent to Imitrex injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the U.S. Sumatriptan injection is used to treat acute migraine with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read